Physician profile
John P Detullio
NPI 1184738940
$3,094.99
in general payments reported to CMS, 2019-2025
26 companies · $48.48 in 2025
The $48.48 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,808 · 2020: $293 · 2021: $212 · 2022: $436 · 2023: $134 · 2024: $163 · 2025: $48.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $345.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $345.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $697.85 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $544.88 | 2019-2024 | Fasenra |
| Genentech USA, INC. | $183.05 | 2019-2022 | |
| Philips North America LLC | $183.00 | 2019-2022 | |
| Mylan Specialty L.P. | $173.19 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $172.85 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.48 | 2019-2022 | |
| Grifols USA, LLC | $136.93 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $118.44 | 2019-2020 | |
| Inspire Medical Systems, INC. | $97.72 | 2023-2024 | Inspire |
| Advanced Respiratory, INC | $86.57 | 2019-2020 | |
| Genzyme Corporation | $67.08 | 2019-2020 | |
| Electromed, INC. | $64.86 | 2019-2024 | Smartvest |
| Actelion Pharmaceuticals US, INC. | $59.58 | 2019-2020 | |
| Insmed, INC. | $59.45 | 2019-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $45.69 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $39.91 | 2019-2020 | |
| La Jolla Pharmaceutical Company | $39.42 | 2019 | |
| Circassia INC. | $27.35 | 2019 | |
| Shire North American Group INC | $26.84 | 2019 | |
| Vapotherm INC | $24.48 | 2019 | |
| Harmony Biosciences LLC | $19.73 | 2025 | |
| Apria Healthcare LLC | $17.73 | 2021 | |
| Pfizer INC. | $15.00 | 2019 | |
| Amgen INC. | $14.76 | 2022 | |
| Merck Sharp & Dohme LLC | $14.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Detullio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.